Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data

Protopopescu, Camélia; Raffi, François; Roux, Perrine; Reynes, Jacques; Dellamonica, P.; Spire, Bruno; Leport, Catherine; Carrieri, Patrizia

doi:10.1093/jac/dkp232

Cited by 97 publications

(79 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another recent study by Arroyo et al found no difference in adherence rates in patients receiving once or twice daily regimens [24]. A French study showed that nonadherence was independently associated with side effects, and having a three times or more daily dosing regimen in comparison to once or twice daily therapy [25].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

et al. 2017

View full text Add to dashboard Cite

raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different definitions of virological failure (VF) and treatment failure (TF) were employed. Kaplan-Meier curves and Cox regression models were performed to estimate time to event probability. Results We included 72 HIV-infected patients, 22 (31%) of these were female, 31 (43%) men who have sex with men (MSM) amd 15 (21%) had hepatitis co-infections. Median age was 44 (IQR: 35-50) years amd CD4 count was 389 (IQR 283-606) cells/mmc. Median follow-up time for TF was 24 (IQR 9-31) months. Twenty-five discontinuations occurred (60% simplifications); only 2 (8%) were toxicity-driven (lipid elevations). The probability of VF (confirmed VL >50 copies/mL) was estimated at 7% [95% confidence interval (CI) 1-13%] by 12 and 9% (95% CI 2-16%) by 24 months. When considering TF, we found a probability of stop/intensification/single VL > 200 copies/ mL of 13% (95% CI 1-17%) and 22% (95% CI 11-33%) by 12 and 24 months. Female gender (adjusted relative hazard, ARH = 0.10; 95% CI 0.01-0.74; p = 0.024) and older age (AHR = 0.50 per 10 years older; 95% CI 0.25-0.99; p = 0.045) were associated with a lower risk of TF. A previous PI failure was strongly associated with TF (AHR = 52.6, 95% CI 3.6-779; p = 0.004). Conclusions DRV/r + RAL is a valuable NRTI-sparing option, especially in female and older patients, with a relatively low risk of VF and good tolerability after 2 years since start in an ART-experienced population. However, previous PI-failure should be a limiting factor for this strategy. AbstractBackground Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

et al. 2017

View full text Add to dashboard Cite

show abstract

“…13 The role of side effects on treatment adherence has been discussed previously for drug-susceptible TB and other diseases that require long-term treatment, such as human immunodefi ciency virus/acquired immunedefi ciency syndrome. [14][15][16][17][18][19][20] The treatment of DR-TB is known to cause frequent severe side effects. [21][22][23] In the project in Yerevan, free, good quality monitoring and management of side effects was provided thanks to MSF support.…”

Section: Discussionmentioning

confidence: 99%

Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

Sánchez-Padilla¹,

Marquer²,

Kalon

et al. 2014

int j tuberc lung dis

View full text Add to dashboard Cite

“…Entre esses obstáculos, o uso de álcool, que é um comportamento modificável, temse mostrado como um forte preditor de falhas na adesão e piora no desfecho clínico [25][26][27][28][29][30][31][32][33][34][35] .…”

Section: Discussionunclassified

Associação entre uso de álcool em indivíduos com AIDS e adesão ao tratamento antirretroviral: uma revisão da literatura

Rego

2010

J. bras. psiquiatr.

View full text Add to dashboard Cite

rESUMo objetivo: O objetivo deste trabalho foi fazer uma revisão sistemática da literatura, utilizando a base de dados MedLine, sobre o tema: uso/abuso/dependência de álcool como um fator de risco à redução da adesão, à redução na supressão da carga viral ou ao pior desfecho clínico em pacientes com AIDS em uso de highly active antiretroviral therapy (HAART). Método: Foi realizada uma pesquisa sistemática na base de dados MedLine utilizando como unitermos "HAART", "adherence" e "alcohol", na busca de artigos que versassem sobre a temática: avaliação ou associação de uso/abuso/dependência de álcool e adesão/supressão da carga viral/ desfecho clínico nos pacientes em uso de terapia antirretroviral. resultados: A busca resultou em 65 artigos. Contudo, apenas 21 deles contemplaram os critérios de inclusão e foram selecionados. Foi encontrada associação positiva entre uso/abuso/dependência de álcool e baixa adesão/baixa supressão da carga viral/pior desfecho clínico em 18 (85,7%) artigos. Conclusão: O uso/abuso/dependência de álcool é um fator de risco para baixa adesão/baixa supressão da carga viral/pior desfecho clínico nos indivíduos em uso de HAART. aBStraCt Objective: The purpose of this work was to make a systematic review of the literature, using the MedLine data basis, about the alcohol usage/abuse/dependence as a risk factor to the adherence reduction, the viral load reduction or even a worse clinical outcome in HIV patients in the usage of highly active antiretroviral therapy (HAART). Method: It was made a systematic research in theMedLine data basis using the words: " HAART", "adherence" and "alcohol"

show abstract

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data

Cited by 97 publications

References 41 publications

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

Associação entre uso de álcool em indivíduos com AIDS e adesão ao tratamento antirretroviral: uma revisão da literatura

Contact Info

Product

Resources

About